CTRCD is prevalent in patients with non-high-risk breast cancer undergoing trastuzumab chemotherapy. Low- and moderate-risk patients show distinct responses to trastuzumab. The LV-GLS is the only deformation index sensitive to early trastuzumab-related cardiac dysfunction.
Keyphrases
- left ventricular
- epidermal growth factor receptor
- metastatic breast cancer
- end stage renal disease
- ejection fraction
- newly diagnosed
- oxidative stress
- chronic kidney disease
- heart failure
- prognostic factors
- acute myocardial infarction
- aortic stenosis
- mitral valve
- high intensity
- radiation therapy
- locally advanced
- patient reported outcomes
- young adults
- aortic valve
- patient reported
- drug induced